Bayer (BAYN: DE) has announced that its Supplemental New Drug Application (sNDA) for Stivarga (regorafenib) will be reviewed under the US Food and Drug Administration’s priority review scheme.
The decision means that the FDA should provide a decision on the German pharma major’s application within six months, boosting hopes that the company can reverse declining sales of the product.
Bayer has submitted an sNDA to market the anti-cancer therapy as a second-line treatment for a type of liver cancer called unresectable hepatocellular carcinoma (HCC).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze